Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06624085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Trial sites reduced: 18 → 9 locations · Eligibility criteria expanded, about 36 words Show 2 more changesShow less
    • Trial sites reduced: 18 → 9 locations
    • Eligibility criteria expanded, about 36 words
  2. Enrollment reopened Study sites: 17 to 18v26 Show 1 more changeShow less
    • Study sites: 17 to 18
  3. Primary and study completion moved earlier from Mar 31, 2030 to Mar 22, 2027 Enrollment closed, study ongoing · Study sites: 18 to 17v25 Show 2 more changesShow less
    • Enrollment closed, study ongoing
    • Study sites: 18 to 17
  4. Site details revised at 1 of 18 sitesv24
  5. Study sites: 17 to 18v23
Show 21 earlier versionsHide 21 earlier versions
  1. Study sites: 16 to 17v22
  2. Re-verified, no change to tracked fieldsv21
  3. Study sites: 15 to 16v20
  4. 2 versions Re-verified since Feb 3, 2026, no change to tracked fieldsv18-v19
  5. Study sites: 14 to 15v17
  6. 3 versions Re-verified since Oct 9, 2025, no change to tracked fieldsv14-v16
  7. Study sites: 12 to 14v13
  8. Start date: Sep 27, 2024 to Apr 28, 2025 Study sites: 11 to 12v12 Show 1 more changeShow less
    • Study sites: 11 to 12
  9. Study sites: 10 to 11v11
  10. Re-verified, no change to tracked fieldsv10
  11. Primary completion date: Mar 31, 2028 to Mar 31, 2030 Study sites: 8 to 10v9 Show 1 more changeShow less
    • Study sites: 8 to 10
  12. Study sites: 6 to 8v8
  13. Re-verified, no change to tracked fieldsv7
  14. Study sites: 5 to 6v6
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 3 to 5 · Primary completion date: Feb 14, 2028 to Mar 31, 2028 · Completion date: Sep 27, 2029 to Mar 31, 2030 · 1 morev5 Show 4 more changesShow less
    • Study sites: 3 to 5
    • Primary completion date: Feb 14, 2028 to Mar 31, 2028
    • Completion date: Sep 27, 2029 to Mar 31, 2030
    • Start date changed from estimate of Jan 31, 2025 to Sep 27, 2024
  16. Start date: Nov 15, 2024 to Jan 31, 2025 Trial status: Recruiting to Not Yet Recruiting · Study sites: 1 to 3 · Completion date: Jan 14, 2030 to Sep 27, 2029v4 Show 3 more changesShow less
    • Trial status: Recruiting to Not Yet Recruiting
    • Study sites: 1 to 3
    • Completion date: Jan 14, 2030 to Sep 27, 2029
  17. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v3 Show 1 more changeShow less
    • Study sites: 0 to 1
  18. Start date: Oct 25, 2024 to Nov 15, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Trial Details
NCT Number NCT06624085
Lead Sponsor Hoffmann-La Roche
Conditions Lymphoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov